Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. develops prescription transdermal pharmaceutical products, with recurring updates centered on its AVERSA abuse-deterrent transdermal technology and a lead abuse-deterrent fentanyl transdermal system. The technology incorporates aversive agents into patches to address abuse, diversion, misuse and accidental exposure involving drugs with abuse potential, including opioids and stimulant drugs.
Company news also covers product distribution activity for kinesiology tapes and mosquito repellent patches, regulatory and intellectual-property steps tied to transdermal products, shareholder meeting matters, and corporate updates involving operating subsidiaries and Nasdaq-listed common stock and warrants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) reported financial results for the fiscal year ending January 31, 2023, highlighting a record revenue of $2.1 million, up 46% from the previous year. Key achievements include a favorable court verdict recovering 15% of total outstanding shares and the announcement of a Seven-for-Six Forward stock split. The company received patent allowance for its AVERSA™ technology in North America and partnered with Kindeva Drug Delivery for enhanced abuse-deterrent characteristics. Despite a net loss of $4.48 million (or $0.53 per share), down from $6.37 million in FY 2022, the results reflect significant operational progress. Research expenses increased to $0.98 million from $0.4 million, while SG&A expenses decreased slightly to $3.9 million. The company aims for commercial growth in 2023 and anticipates AVERSA™ to achieve annual sales between $80 million and $200 million.
Nutriband (NASDAQ:NTRB, NTRBW), recognized for its innovative transdermal solutions, is set to present at the Planet MicroCap Showcase: VEGAS 2023 on April 26, 2023, at 08:30 AM PST. CEO Gareth Sheridan will lead the presentation, followed by a Q&A session.
To join the live presentation, access the webcast here. For those interested in one-on-one investor meetings during the event in Las Vegas, registration is available here.
Nutriband is advancing its abuse deterrent fentanyl patch utilizing the patented AVERSA technology, aimed at mitigating drug misuse and exposure risks.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a partnership with Kindeva Drug Delivery to advance the AVERSA™ Fentanyl formulation into commercial manufacturing. The AVERSA™ Fentanyl product utilizes Nutriband's proprietary abuse-deterrent technology and is projected to achieve peak U.S. sales between $80M and $200M. This collaboration aims to develop the first abuse-deterrent fentanyl patch, enhancing safety and accessibility for patients. The technology is supported by a robust intellectual property portfolio, with patents granted in multiple countries.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has secured a $2 million credit line to support the FDA approval process and commercial manufacturing of its lead product, AVERSA™ Fentanyl, an abuse-deterrent transdermal system. This technology combines Nutriband's proprietary methods with an FDA-approved fentanyl patch system, offering significant market potential, estimated at $80M - $200M in annual US sales. CEO Gareth Sheridan emphasized that this non-dilutive financing is crucial for their growth strategy and ongoing commercialization efforts. The AVERSA™ technology is backed by a robust intellectual property portfolio spanning multiple countries.